相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis
Patsuree Cheebsumon et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells
Quang-De Nguyen et al.
TRANSLATIONAL ONCOLOGY (2011)
Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis
Kathrine Roe et al.
ACTA ONCOLOGICA (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas
Matthias R. Benz et al.
CLINICAL CANCER RESEARCH (2009)
[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
Wen Wee Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
Kaiyumars B. Contractor et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non-Small Cell Lung Cancer with the mTOR Inhibitor Everolimus
Lucia Nogova et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards
Qinan Bao et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Monitoring and Predicting Response to Therapy with F-18-FDG PET in Colorectal Cancer: A Systematic Review
Lioe-Fee de Geus-Oei et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
The mTOR kinase inhibitor AZD8055 modulates 18F-FDG uptake in vivo in the human glioma xenograft model U87-MG
Heather Keen et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting phosphoinositide 3-kinase - Moving towards therapy
Romina Marone et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
Liu Hua Wei et al.
CLINICAL CANCER RESEARCH (2008)
Tumor cell metabolism imaging
Christian Plathow et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
Noriaki Sunaga et al.
LUNG CANCER (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival
Elizabeth A. Kidd et al.
CANCER (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Measurement of input functions in rodents: challenges and solutions
R Laforest et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Dependence of FDG uptake on tumor microenvironment
A Pugachev et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Akt stimulates aerobic glycolysis in cancer cells
RL Elstrom et al.
CANCER RESEARCH (2004)
Targeting the PI3K-Akt pathway in human cancer: Rationale and promise
J Luo et al.
CANCER CELL (2003)
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
S Stroobants et al.
EUROPEAN JOURNAL OF CANCER (2003)
分享论文
